Martin Olin, CFO and Deputy CEO, promoted to Chief Executive Officer
Sunstone Life Science Fund I portfolio company Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Kirsten Drejer, M.Sc., Ph. D., Co-founder, Chief Executive Officer and Director will transition from an executive operational role to an independent member of the Board of Directors. In parallel, Martin Olin, M.Sc., E*MBA, now Chief Financial Officer, has been promoted effective 1st September to Chief Executive Officer and member of the Board of Directors. Kirsten Drejer is proposed to be elected to the Board of Directors as an independent member and will, through a transition period, be a working Board member assisting Martin Olin.